SCHEMBL8675616

SCHEMBL8675616

COc1ccc(/C=C(/c2ccc(OCc3ccccc3)cc2)N(C)C)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.60
GSK3B P49841 1/20 0.53
BACE1 P56817 1/20 0.53
RAB9A P51151 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPC1 O15118 2/20 0.52
POLB P06746 1/20 0.52
NR1H4 Q96RI1 1/20 0.50
EGFR P00533 3/20 0.49
NR4A1 P22736 1/20 0.49
NR4A2 P43354 1/20 0.49
NR4A3 Q92570 1/20 0.49
TP53 P04637 1/20 0.48
PKM P14618 1/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
MRGPRX4 Q96LA9 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
APP P05067 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8675617 1.00 MAOB (0.60) MAOBGSK3BBACE1RAB9ASMN1; SMN2
SCHEMBL8676691 1.00 MAOB (0.60) MAOBGSK3BBACE1RAB9ASMN1; SMN2
SCHEMBL8809160 0.90 NR1H4 (0.56) MAOBRAB9ASMN1; SMN2NPC1NR1H4
SCHEMBL9837797 0.85 KDM4E (0.66) MAOBGSK3BBACE1RAB9ASMN1; SMN2
SCHEMBL9839473 0.85 KDM4E (0.66) MAOBGSK3BBACE1RAB9ASMN1; SMN2
SCHEMBL9839479 0.85 KDM4E (0.66) MAOBGSK3BBACE1RAB9ASMN1; SMN2
SCHEMBL10800845 0.84 ALDH1A1 (0.61) MAOBSMN1; SMN2NFKB1
SCHEMBL10800841 0.84 ALDH1A1 (0.61) MAOBSMN1; SMN2NFKB1
SCHEMBL9838120 0.82 KDM4E (0.61) MAOBGSK3BBACE1RAB9ASMN1; SMN2
SCHEMBL9838123 0.82 KDM4E (0.61) MAOBGSK3BBACE1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5750708-A Pyridine compounds intermediates processes compositions and methods ELI LILLY AND COMPANY (US) 1998-05-12 US disclosed
US-5672609-A POSTMENOPAUSAL SYNDROME; ANTILIPEMIC AND -CARCINOGENIC AGENTS; OSTEOPOROSIS; CARDIOTONIC AGENTS; RESTENOSIS; SIDE EFFECT REDUCTION COMPARED TO ESTROGEN ELI LILLY AND COMPANY (US) 1997-09-30 US disclosed
WO-1997004778-A1 PYRIDINE COMPOUNDS, INTERMEDIATES, PROCESSES, COMPOSITIONS, AND METHODS ELI LILLY AND COMPANY (US) 1997-02-13 WO disclosed